Fortress Biotech · 8 hours ago
Director of Business Development
Fortress Biotech is an innovative life sciences company focused on acquiring, developing, and commercializing therapeutic products. They are seeking a motivated individual to join their Business Development team, responsible for networking and maintaining relationships with key opinion leaders and industry partners.
BiotechnologyHealth CareLife SciencePharmaceutical
Responsibilities
Identifying clinical stage and ex-USA approved drug candidates for acquisition or license from key academic, corporate or other entities involved in drug research and development
Networking extensively, including significant cold outreach, to establish and maintain relationships with leading academic researchers, clinicians and industry leaders; maintain list of contacts in our CRM for networking and news distribution
Engaging with key opinion leaders in targeted therapeutic categories to find new product opportunities
Qualification
Required
Medical degree is required
Must be eligible to work in the United States
Driven and disciplined individual looking to build a career in the biopharmaceutical industry
Naturally curious learner who is excited to dive into many different drug candidates and therapeutic areas
Able to network extensively and engage both academic and commercial sectors of biopharma
Comfortable on the phone and in virtual meetings
Exceptional organizational, analytical, interpersonal, and written and verbal communication skills
Ability to work independently, as well as in a collaborative manner with other teams in the company
Cultivate substantive relationships and credibility with internal and external parties
Preferred
Remote preferred
Company
Fortress Biotech
Fortress Biotech is a biopharmaceutical company that focuses on acquiring, developing, and commercializing therapeutic products.
Funding
Current Stage
Public CompanyTotal Funding
$204.83MKey Investors
Oaktree Capital ManagementHercules CapitalNational Securities Corporation
2024-09-20Post Ipo Equity· $8M
2023-12-29Post Ipo Equity· $11M
2023-11-10Post Ipo Equity· $10M
Recent News
2026-01-14
2026-01-13
2025-12-16
Company data provided by crunchbase